MCID: CNS004
MIFTS: 58

Constipation

Categories: Gastrointestinal diseases

Aliases & Classifications for Constipation

MalaCards integrated aliases for Constipation:

Name: Constipation 12 29 6 42 43 15 32

Classifications:



External Ids:

Disease Ontology 12 DOID:2089
ICD9CM 34 564.0 564.00
MeSH 43 D003248
NCIt 49 C37930
SNOMED-CT 67 14760008
ICD10 32 K59.0 K59.00
UMLS 71 C0009806

Summaries for Constipation

MedlinePlus : 42 Constipation means that a person has three or fewer bowel movements in a week. The stool can be hard and dry. Sometimes it is painful to pass. At one time or another, almost everyone gets constipated. In most cases, it lasts a short time and is not serious. There are many things you can do to prevent constipation. They include Eating more fruits, vegetables and grains, which are high in fiber Drinking plenty of water and other liquids Getting enough exercise Taking time to have a bowel movement when you need to Using laxatives only if your doctor says you should Asking your doctor if medicines you take may cause constipation It's not important that you have a bowel movement every day. If your bowel habits change, however, check with your doctor. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Constipation is related to irritable bowel syndrome and hirschsprung disease 1. An important gene associated with Constipation is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Ondansetron and Cyclobenzaprine have been mentioned in the context of this disorder. Affiliated tissues include colon, breast and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A bowel dysfunction that is characterized by infrequent or difficult evacuation of feces.

Wikipedia : 74 Constipation refers to bowel movements that are infrequent or hard to pass. The stool is often hard and... more...

Related Diseases for Constipation

Diseases related to Constipation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 712)
# Related Disease Score Top Affiliating Genes
1 irritable bowel syndrome 33.5 VIP TACR1 TAC1 SST SLC6A4 PYY
2 hirschsprung disease 1 33.4 VIP TAC1 RET KIT GDNF CALCA
3 intestinal pseudo-obstruction 33.4 SST RET FLNA
4 hypoganglionosis 33.2 RET GDNF
5 neurogenic bowel 33.2 VIP TAC1 MLN
6 intestinal obstruction 33.2 SST RET MLN KIT GDNF FLNA
7 eating disorder 33.0 SLC6A4 PYY OPRM1 CCK
8 central hypoventilation syndrome, congenital 32.7 TACR1 TAC1 SLC6A4 RET GDNF
9 primary hyperparathyroidism 32.7 RET GAST CALCA
10 diarrhea 32.1 TAC1 SST SLC6A4 PYY OPRM1 MLN
11 megacolon 32.1 VIP TAC1 RET KIT GDNF
12 ileus 31.8 VIP SST OPRM1 MLN CCK CALCA
13 anismus 31.8 VIP CLCN2
14 gastroesophageal reflux 31.6 VIP PYY MLN GAST CCK
15 pain agnosia 31.4 TACR1 TAC1 OPRM1 HTR3A CCK CALCA
16 gastroparesis 31.4 SST MLN HTR3A GAST CCK
17 achalasia 31.4 VIP RET KIT GDNF GAST
18 colonic pseudo-obstruction 31.4 VIP SST MLN HTR4
19 paralytic ileus 31.3 OPRM1 MLN HTR3A
20 gastrointestinal system disease 31.3 MLN HTR4 GAST CCK
21 anxiety 31.2 TAC1 SLC6A4 OPRM1 HTR3A CCK
22 carcinoid syndrome 31.2 SST PYY HTR3A CALCA
23 autonomic neuropathy 31.2 MLN GAST CCK
24 multiple endocrine neoplasia 31.2 RET GDNF CALCA
25 functional diarrhea 31.2 HTR3A CLCN2
26 hydrocephalus 31.1 VIP SST GDNF FLNA
27 headache 31.1 TAC1 CCK CALCA
28 gastroenteritis 31.0 PYY MLN CALCA
29 carcinoid tumors, intestinal 31.0 SST GAST
30 rare tumor 30.9 SST RET KIT
31 multiple endocrine neoplasia, type iib 30.9 RET GDNF CALCA
32 ganglioneuroma 30.9 VIP SST RET
33 fibromyalgia 30.9 TACR1 SLC6A4 OPRM1 HTR3A CALCA
34 duodenal ulcer 30.8 SST MLN GAST CCK CALCA
35 migraine with or without aura 1 30.8 VIP TACR1 TAC1 SLC6A4 PPOX OPRM1
36 peripheral nervous system disease 30.8 TAC1 OPRM1 GDNF CALCA
37 pheochromocytoma 30.8 VIP SST RET MLN KIT GDNF
38 obsessive-compulsive disorder 30.8 SST SLC6A4 HTR3A CCK
39 psychotic disorder 30.7 SLC6A4 OPRM1 HTR3A CCK
40 drug dependence 30.7 SLC6A4 OPRM1 HTR3A
41 functional colonic disease 30.7 VIP SST MLN
42 neuroma 30.7 RET GDNF CALCA
43 somatoform disorder 30.7 TACR1 TAC1 SLC6A4 OPRM1 HTR3A CALCA
44 neuroblastoma 30.7 VIP SST RET OPRM1 KIT GDNF
45 small cell carcinoma 30.6 KIT GAST CALCA
46 gallbladder disease 30.6 SST PYY MLN CCK
47 dumping syndrome 30.6 SST PYY MLN GAST CCK
48 cystitis 30.6 TACR1 TAC1 KIT GDNF
49 paraganglioma 30.6 SST RET KIT CALCA
50 hyperparathyroidism 30.6 RET GAST CALCA

Graphical network of the top 20 diseases related to Constipation:



Diseases related to Constipation

Symptoms & Phenotypes for Constipation

GenomeRNAi Phenotypes related to Constipation according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR3A MLN SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR3A MLN SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR3A MLN SLC6A4

MGI Mouse Phenotypes related to Constipation:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 CLCN2 FLNA GDNF HTR3A HTR4 KIT
2 homeostasis/metabolism MP:0005376 10.2 CCK CLCN2 FLNA GAST HTR3A HTR4
3 digestive/alimentary MP:0005381 10.1 CLCN2 FLNA GAST GDNF KIT OPRM1
4 endocrine/exocrine gland MP:0005379 10.07 CCK CLCN2 GAST GDNF HTR3A KIT
5 immune system MP:0005387 10 CLCN2 FLNA GAST GDNF HTR3A KIT
6 nervous system MP:0003631 9.97 CCK CLCN2 FLNA GDNF HTR3A HTR4
7 normal MP:0002873 9.61 FLNA KIT OPRM1 PYY RET SLC6A4
8 renal/urinary system MP:0005367 9.17 CCK GDNF HTR3A KIT PPOX RET

Drugs & Therapeutics for Constipation

Drugs for Constipation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 665)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ondansetron Approved Phase 4 99614-02-5 4595
2
Cyclobenzaprine Approved Phase 4 303-53-7 2895
3
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
4
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204
5
Piroxicam Approved, Investigational Phase 4 36322-90-4 54676228 5280452
6
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
7
Orphenadrine Approved Phase 4 83-98-7 4601
8
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
9
Linaclotide Approved Phase 4 851199-59-2 65351
10
Sorbitol Approved Phase 4 50-70-4 5780
11
Simethicone Approved Phase 4 8050-81-5
12
Methadone Approved Phase 4 76-99-3 4095
13
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
14
Octreotide Approved, Investigational Phase 4 83150-76-9 6400441 383414
15
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
16
Alverine Approved, Investigational Phase 4 150-59-4 3678
17
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
18
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
19
Coal tar Approved Phase 4 8007-45-2
20
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
21
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
22
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
23
Metronidazole Approved Phase 4 443-48-1 4173
24
Topiramate Approved Phase 4 97240-79-4 5284627
25
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
26
Desflurane Approved Phase 4 57041-67-5 42113
27 Apricot Approved Phase 4
28
Gliclazide Approved Phase 4 21187-98-4 3475
29
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
30
Metformin Approved Phase 4 657-24-9 4091 14219
31
Dihydrocodeine Approved, Illicit Phase 4 125-28-0
32
Labetalol Approved Phase 4 36894-69-6 3869
33
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
34
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
35
Propranolol Approved, Investigational Phase 4 525-66-6 4946
36
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
37
Ferrous succinate Approved Phase 4 10030-90-7
38
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
39
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
40
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
41
Chlorzoxazone Approved Phase 4 95-25-0 2733
42
Palonosetron Approved, Investigational Phase 4 119904-90-4, 135729-61-2, 135729-56-5 148211
43
4-Aminopyridine Approved Phase 4 504-24-5 1727
44
Lactulose Approved Phase 4 4618-18-2 11333
45
Morphine Approved, Investigational Phase 4 57-27-2 5288826
46
Alvimopan Approved, Investigational Phase 4 156053-89-3 5488548
47
tannic acid Approved Phase 4 1401-55-4
48
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
49
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
50
Magnesium oxide Approved Phase 4 1309-48-4 14792

Interventional clinical trials:

(show top 50) (show all 1534)
# Name Status NCT ID Phase Drugs
1 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
2 Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section Unknown status NCT02571881 Phase 4 Oxycodone;oxycodone-naloxone
3 Polyethylene Glycol for Childhood Constipation Unknown status NCT01875744 Phase 4 Polyethylene glycol 4000
4 The Assessment of Lactobacillus Reuteri Efficacy, Provided With Forlax, as Treatment of Incurable Constipation in Children 3-7 Years. Double Blind, Placebo-controlled, Randomized and Multicenter Trial Unknown status NCT01388712 Phase 4
5 An Evaluation of the Efficacy and Safety of a Polyethylene Glycol (PEG) Based Bowel Protocol for the Management of Constipation in Peritoneal Dialysis Patients: A Pilot Study Unknown status NCT03148002 Phase 4 Current Bowel Protocol (senna/lactulose);PEG Bowel Protocol (PEG/lactulose)
6 Comparing a Probiotic and Non-probiotic Intervention in Their Ability to Improve Bowel Habits of Residents in Nursing Homes Unknown status NCT02949882 Phase 4
7 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome- a Double Blind, Placebo - Controlled, Randomized Study Unknown status NCT01779765 Phase 4
8 Randomized Controlled Trial Comparing the Efficacy of Polyethylene Glycol Alone and Polyethylene Glycol Combined With Topical Diltiazem in Treating Anal fissure in Children Unknown status NCT02419534 Phase 4 Polyethylene glycol;Polyethylene glycol with Diltiazem
9 Multicenter Study Evaluating the Efficacy of Dicopeg Junior in Comparison With Lactulose for the Treatment of Functional Constipation in Children Aged 6 Months to 6 Years. A Prospective, Randomized Study. Unknown status NCT03177434 Phase 4 polyethylene glycols (PEG) 3350;Lactulose Oral Product
10 The Clinical Use of Probiotics in the Uremia Patients Under Chronic Peritoneal Dialysis Unknown status NCT01076426 Phase 4 Pro-biotics
11 A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trials to Evaluate the Efficacy and Safety of Runzao Zhiyang Capsule in Treating Chronic Eczema Unknown status NCT02601222 Phase 4 Runzao zhiyang capsule;Runzaozhiyang capsule agent simulation;Urea cream
12 A Prospective, Randomized Controlled Trial Comparing the Efficacy and Patient Tolerability of MiraLAX (PEG 3350) vs Golytely as Bowel Preparation for Screening Colonoscopy Unknown status NCT00889655 Phase 4 Golytely (polyethylene glycol);MiraLax (polyethylene glycol 3350)
13 Efficacy of Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopy Unknown status NCT02781493 Phase 4 2 mg Prucalopride plus 2 L Polyethylene Glycol regimen;2 mg Placebo plus 2 L Polyethylene Glycol regimen
14 Changes of Heart Rate Variability in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4 Aripiprazole; Quetiapine
15 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Comparison Clinical Study to Investigate the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron With Overactive Bladder Symptoms in Men Unknown status NCT02361502 Phase 4 mirabegron;placebo
16 Ureteral Stent-related Pain and Mirabegron (SPAM) Trial Unknown status NCT02095665 Phase 4 Mirabegron;Tamsulosin;Tylenol #3
17 Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
18 Probiotics After Discharge (PAD) Study: Impact on Microbiome, Health and Growth Outcomes Unknown status NCT02695784 Phase 4
19 Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying Unknown status NCT02510976 Phase 4 prucalopride;placebo
20 A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study Unknown status NCT02472210 Phase 4 Botulinum Toxin
21 Randomized Placebo Controlled Trial of Postoperative Pain After Intravenous Vitamin C Injection for Arthroscopic Rotator Cuff Repair Unknown status NCT02992028 Phase 4 Intravenous Nutrition (Vitamins) injection;Intravenous Saline injection
22 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
23 Solifenacin vs Levofloxacin vs Lornoxicam for Management of Intravesical Instillation of Bacillus Calmette-Guerin (BCG) Side Effects A Single Blinded Randomised Controlled Study Unknown status NCT03038321 Phase 4 sofenacin;Tavanic;Xefo
24 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
25 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
26 An Eight Week, Double-Blind Efficacy Study of Cyclobenzaprine ER (Amrix TM) Augmentation to Alleviate Fibromyalgia Fatigue and Muscle Pain Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
27 Bilateral Transversus Abdominis Plane Block With or Without Magnesium for Total Abdominal Hysterectomy With or Without Salpingo-oophorectomy: a Randomized Controlled Trial Unknown status NCT02680626 Phase 4 Magnesium Sulfate;Ropivacaine
28 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial. Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;Morphine Sulfate;Fentanyl;Dilaudid;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
29 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
30 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
31 Comparative Study of Antiemetic Effect of Ramosetron With Combination of Ondansetron and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy Unknown status NCT02803788 Phase 4 ramosetron, ondansetron, dexamethasone
32 The ACT-OUT Trial: ACTivity OUTcomes Based on the Consumption of a High Carbohydrate or High Fat Diet in Patients With Metabolic Syndrome Unknown status NCT01357382 Phase 4
33 Sacral Nerve Stimulation for Anal Incontinence and Bowel Control Completed NCT00200005 Phase 4
34 PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children Completed NCT00153114 Phase 4 polyethyleneglycol3350
35 A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation Completed NCT00171522 Phase 4 Tegaserod and Polyethylene Glycol 3350
36 Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation Completed NCT00153140 Phase 4 polyethyleneglycol3350
37 Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery Completed NCT02573922 Phase 4 oxycodone-naloxone;Oxycodone
38 A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children Completed NCT00319670 Phase 4 MiraLax
39 Effects of Lubiprostone on Gastric Sensory and Motor Function in Patients With Chronic Idiopathic Constipation Completed NCT01460225 Phase 4 lubiprostone
40 Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications Completed NCT01096290 Phase 4 lubiprostone;Matched placebo
41 A Randomized, Double-Blind, Placebo-Controlled Study Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Adults With Advanced Illness And Opioid-Induced Constipation: Efficacy, Safety, And Additional Health Outcomes Completed NCT00672477 Phase 4 Methylnaltrexone;Placebo
42 An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients Completed NCT00164125 Phase 4 polyethyleneglycol3350
43 Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients Completed NCT00153153 Phase 4 polyethyleneglycol3350
44 A Multi-center, Open-labeled Study of the Safety, Efficacy, and Pharmacokinetics of Lubiprostone in Pediatric Patients With Constipation Completed NCT00452335 Phase 4 Lubiprostone;Lubiprostone;Lubiprostone
45 Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation Completed NCT00149877 Phase 4 Tegaserod
46 Comparison of Braintree PolyethyleneGlycol(PEG) Laxative and Placebo for Relief of Constipation From Constipating Medications Completed NCT00153127 Phase 4 polyethyleneglycol3350
47 A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children Completed NCT00583609 Phase 4 PEG3350
48 Open-Label Extension Study To Assess The Safety Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Subjects With Advanced Illness And Opioid-Induced Constipation Completed NCT00672139 Phase 4 Methylnaltrexone bromide
49 The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study Completed NCT02726295 Phase 4 E. coli Nissle 1917(Mutaflor®);Placebo
50 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit Completed NCT00844831 Phase 4 Lubiprostone

Search NIH Clinical Center for Constipation

Cochrane evidence based reviews: constipation

Genetic Tests for Constipation

Genetic tests related to Constipation:

# Genetic test Affiliating Genes
1 Constipation 29

Anatomical Context for Constipation

MalaCards organs/tissues related to Constipation:

40
Colon, Breast, Testes, Lung, Spinal Cord, Prostate, Liver

Publications for Constipation

Articles related to Constipation:

(show top 50) (show all 22802)
# Title Authors PMID Year
1
Transcutaneous posterior tibial nerve stimulation in children and adolescents with functional constipation: A protocol for an interventional study. 42 61
31702626 2019
2
Botulinum toxin injection for internal anal sphincter achalasia after pull-through surgery in Hirschsprung disease. 61 42
31702647 2019
3
Plecanatide for the treatment of chronic idiopathic constipation in adult patients. 42 61
31575291 2019
4
Gastrointestinal Care of the Parkinson Patient. 61
31733704 2020
5
Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics. 61
31806082 2020
6
An integrated metabolomics strategy to reveal dose-effect relationship and therapeutic mechanisms of different efficacy of rhubarb in constipation rats. 61
31493746 2020
7
Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. 61
30996042 2020
8
Inventing a herbal tradition: The complex roots of the current popularity of Epilobium angustifolium in Eastern Europe. 61
31580942 2020
9
Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? 61
31669925 2020
10
GUT MICROBIOTA AND THE USE OF PROBIOTICS IN CONSTIPATION IN CHILDREN AND ADOLESCENTS: SYSTEMATIC REVIEW. 61
31778407 2020
11
Self-Efficacy in Children with Functional Constipation Is Associated with Treatment Success. 61
31679634 2020
12
Physiotherapy for Children with Functional Constipation: A Pragmatic Randomized Controlled Trial in Primary Care. 61
31732133 2020
13
MASCC recommendations on the management of constipation in patients with advanced cancer. 61
31396746 2020
14
Nigral overexpression of α-synuclein in a rat Parkinson's disease model indicates alterations in the enteric nervous system and the gut microbiome. 61
31576631 2020
15
Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS. 61
30923071 2020
16
Regular, sustained-release morphine for chronic breathlessness: a multicentre, double-blind, randomised, placebo-controlled trial. 61
31558624 2020
17
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. 61
31742767 2020
18
The effect and safety of acupuncture on patients with functional constipation: Protocol for a systematic review and meta-analysis of high quality RCTs. 61
31804322 2019
19
Patients' Self-Assessment of the Symptoms and Impact of Opioid-Induced Constipation: Results From a Prospective, Observational Cohort Study of Japanese Patients With Cancer. 61
31805362 2019
20
Correction of Dyssynergic Defecation, but not Fiber Supplementation, Reduces Symptoms of Functional Dyspepsia in Patients With Constipation in a Randomized Trial. 61
31811952 2019
21
Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis. 61
31826058 2019
22
Effectiveness and safety of light vegetarian diet on functional constipation with gastrointestinal damp-heat pattern: An exploratory study protocol for randomized controlled trial. 61
31852124 2019
23
The prevalence of functional constipation in children was unchanged after the Rome IV criteria halved the diagnosis period in Rome III. 61
31140192 2019
24
Gastrointestinal Motility Issues in Cancer Patients. 61
31823129 2019
25
Complicated diverticulitis mimicking colonic carcinoma: combined approach with endoscopy and budesonide. 61
31801775 2019
26
The motor prodromes of parkinson's disease: from bedside observation to large-scale application. 61
31802219 2019
27
pKa of opioid ligands as a discriminating factor for side effects. 61
31852967 2019
28
Pretest and Post-test Probabilities of Diagnoses of Rectal Evacuation Disorders Based on Symptoms, Rectal Exam, and Basic Tests: a Systematic Review. 61
31811949 2019
29
Synthesis and Pharmacological Evaluation of Hybrids Targeting Opioid and Neurokinin Receptors. 61
31817441 2019
30
Abundance of Probiotics and Butyrate-Production Microbiome Manages Constipation via Short-Chain Fatty Acids Production and Hormones Secretion. 61
31556210 2019
31
Scientific solution to a complex problem: physiology and multidisciplinary team improve understanding and outcome in chronic constipation and faecal incontinence. 61
31844977 2019
32
Effect of abdominal massage on constipation and quality of life in older adults: A randomized controlled trial. 61
31780015 2019
33
Effects of bilateral transcutaneous tibial nerve stimulation on constipation severity in geriatric patients: A prospective clinical study. 61
31793185 2019
34
Lotus seed oligosaccharides at various dosages with prebiotic activity regulate gut microbiota and relieve constipation in mice. 61
31568850 2019
35
Transcutaneous electrical nerve stimulation of acupuncture points enhances therapeutic effects of oral lactulose solution on opioid-induced constipation. 61
31774002 2019
36
Outcomes following stoma formation in patients with spinal cord injury. 61
31274228 2019
37
Gastrointestinal Manifestations in Hereditary Transthyretin Amyloidosis associated with Glu89Gln Mutation. 61
31826067 2019
38
Gastrointestinal Symptoms in Infants of Mothers With a Psychiatric History and the Role of Depression and Bonding. 61
31517718 2019
39
Scoping review of symptoms in children with rare, progressive, life-threatening disorders. 61
31831511 2019
40
Gorham-Stout disease in the rib and thoracic spine with spinal injury treated with radiotherapy, zoledronic acid, vitamin D, and propranolol: A case report and literature review. 61
31798875 2019
41
[Anorectal disorders in patients with multiple sclerosis: Physiopathology, prevalence, impact, and management]. 61
31521507 2019
42
Diagnosis of Hirschsprung Disease. 61
31791203 2019
43
Susceptibility to diarrhea is related to hemodynamic markers of sympathetic activation in the general population. 61
31791149 2019
44
Prucalopride: An Opportunity to Simultaneously Address Gastroparesis and Chronic Constipation. 61
31592785 2019
45
Prevalence and risk factors of overactive bladder in Chinese children: A population-based study. 61
31804751 2019
46
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions. 61
31707815 2019
47
Nutritional status of human T-lymphotropic virus 1 patients: A retrospective study. 61
31677708 2019
48
Physical activity and prodromal features of Parkinson disease. 61
31719136 2019
49
Pediatric Sigmoid Volvulus. 61
29596283 2019
50
Diagnosis and surgical approach of adult Hirschsprung's disease: About two observations and review of the literature. Case series. 61
31719978 2019

Variations for Constipation

ClinVar genetic disease variations for Constipation:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RET NM_020975.6(RET):c.2753T>C (p.Met918Thr)SNV Pathogenic 13919 rs74799832 10:43617416-43617416 10:43121968-43121968
2 46;XY;t(9;11)(q34;p11.2)dnTranslocation Pathogenic 267847
3 46;XX;t(7;13)(p13;q34)dnTranslocation Pathogenic 267841
4 46;XX;t(19;21)(q13.3;q22.3)dnTranslocation Pathogenic 268035
5 PPOX NM_001122764.3(PPOX):c.1353T>G (p.Tyr451Ter)SNV Pathogenic 523355 rs148292941 1:161140885-161140885 1:161171095-161171095
6 COL17A1 NM_000494.4(COL17A1):c.4143_4144AG[1] (p.Glu1382fs)short repeat Pathogenic 599000 rs765243124 10:105793710-105793714 10:104033953-104033956
7 46;X;t(Y;16)(q11.23;p11.2);t(6;21)(p21.3;p13)dnTranslocation Likely pathogenic 267834
8 MT-TP , MT-TT m.15923A>GSNV Conflicting interpretations of pathogenicity 39575 rs1556424691 MT:15923-15923 MT:15923-15923
9 ARID1B NM_020732.3(ARID1B):c.4110G>A (p.Pro1370=)SNV Conflicting interpretations of pathogenicity 210291 rs797045277 6:157520041-157520041 6:157198907-157198907
10 LSM1 NM_014462.3(LSM1):c.231+4A>CSNV Uncertain significance 623485 rs775468919 8:38027316-38027316 8:38169798-38169798

Expression for Constipation

Search GEO for disease gene expression data for Constipation.

GO Terms for Constipation

Cellular components related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.91 TAC1 SST PYY KIT GDNF GAST
2 integral component of plasma membrane GO:0005887 9.81 TACR1 SLC6A4 RET OPRM1 KIT HTR4
3 axon GO:0030424 9.77 TAC1 RET OPRM1 HTR3A CCK
4 extracellular region GO:0005576 9.7 VIP TAC1 SST PYY MLN GDNF
5 integral component of presynaptic membrane GO:0099056 9.58 SLC6A4 OPRM1 HTR3A
6 integral component of postsynaptic membrane GO:0099055 9.5 SLC6A4 OPRM1 HTR3A
7 neuronal cell body GO:0043025 9.17 TAC1 SST RET HTR3A FLNA CCK

Biological processes related to Constipation according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.85 VIP TACR1 RET OPRM1 KIT HTR4
2 response to drug GO:0042493 9.8 SST SLC6A4 RET PPOX
3 chemical synaptic transmission GO:0007268 9.76 TAC1 SST HTR4 HTR3A
4 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.58 VIP TACR1 OPRM1
5 neuropeptide signaling pathway GO:0007218 9.56 TAC1 PYY OPRM1 CALCA
6 regulation of sensory perception of pain GO:0051930 9.5 VIP OPRM1 CCK
7 enteric nervous system development GO:0048484 9.48 RET GDNF
8 tachykinin receptor signaling pathway GO:0007217 9.43 TACR1 TAC1
9 detection of abiotic stimulus GO:0009582 9.37 TACR1 TAC1
10 G protein-coupled receptor signaling pathway GO:0007186 9.36 VIP TACR1 TAC1 SST PYY OPRM1
11 response to pain GO:0048265 9.26 TACR1 TAC1 RET CALCA

Molecular functions related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide hormone receptor binding GO:0051428 9.26 VIP CCK
2 hormone activity GO:0005179 9.17 VIP SST PYY MLN GAST CCK
3 serotonin binding GO:0051378 9.16 SLC6A4 HTR3A
4 neuropeptide hormone activity GO:0005184 9.13 VIP PYY CCK

Sources for Constipation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....